Reviewed by 
When we first told you about this test back in 2020, researchers called it a breakthrough. Six years later, the test is FDA-cleared, commercially available, and transforming how doctors diagnose memory loss. Here's the full story — and how to get tested.
Key Takeaways
• Early detection breakthrough: A blood test measuring p-tau217 can identify Alzheimer’s-related brain changes up to 20 years before symptoms appear.
• FDA milestone: In 2025, the first p-tau217 blood test received FDA clearance to help diagnose Alzheimer’s disease.
• A predictive biomarker: Researchers now believe p-tau217 may act as an “Alzheimer’s clock,” estimating how far someone may be from developing symptoms.
What We Reported in 2020
Back in 2020, we told you about a simple blood test that could detect Alzheimer's disease up to 20 years before the first symptoms appear. At the time, the findings were electrifying. Researchers from the U.S. and Sweden had studied 1,400 patients and found that a protein called p-tau217 could identify Alzheimer's-type brain changes with roughly 90–96% accuracy, rivaling expensive PET scans and invasive spinal fluid tests.
What is P-tau217?
P-tau217 stands for phosphorylated tau-217. It'is a biomarker in the blood or cerebrospinal fluid that signals the presence of Alzheimer’s disease–related changes in the brain. It is a modified form of the tau protein, which normally helps stabilize the internal structure of neurons.
What Tau Normally Does
Tau proteins act like scaffolding inside nerve cells. They help stabilize structures called microtubules, which function like tracks that transport nutrients and signals throughout brain cells.
What Happens in Alzheimer’s Disease
In Alzheimer’s disease, tau proteins become abnormally phosphorylated (a chemical modification where phosphate groups attach to the protein). When this happens:
Tau loses its ability to stabilize neurons.
It begins to clump together into “tau tangles” inside brain cells.
These tangles disrupt communication between neurons and eventually contribute to cell death and cognitive decline.
Experts we quoted back in 2020 didn't hold back. Dr. Michael Weiner of UCSF called the blood test "a breakthrough." Harvard's Rudolph Tanzi said it had "the promise to make early detection possible, before we have symptoms." Dr. Howard Fillit of the Alzheimer's Drug Discovery Foundation called it "a real game changer."
We also told you that in people with a genetic form of Alzheimer's, p-tau217 levels were elevated seven-fold and began rising a full 20 years before any cognitive decline, and that the test could be widely available within three years. That three-year prediction turned out to be accurate. The test is now available. Here's what's happened since.
The Science Gets Even Stronger
Tau Still Outperforms Amyloid
In 2020, we explained why tau, and specifically p-tau217, appears to be a more reliable marker of Alzheimer's disease than amyloid beta plaques, the protein that has dominated research for decades. That finding has held up. Multiple large studies have now confirmed that p-tau217 consistently outperforms amyloid-beta ratios and the earlier p-tau181 marker for detecting Alzheimer's pathology and distinguishing it from other forms of dementia.
Extraordinary Diagnostic Accuracy
In study after study, plasma p-tau217 has matched the results of amyloid and tau PET scans with striking consistency — accuracy rates above 90%, and above 96% for catching early amyloid pathology. For patients already showing symptoms, the blood test correctly identifies Alzheimer's-type changes 85–95% of the time. In some groups, it has performed on par with a PET scan — at a fraction of the cost and without the radiation.
A "Clock" That Can Predict Symptom Onset
In a landmark 2026 study published in Nature Medicine, researchers demonstrated that plasma p-tau217 alone can stage Alzheimer's pathology across the full disease continuum from early amyloid accumulation (Thal phase) through advanced tau spread (Braak stage). Even more remarkably, once a person's p-tau217 crosses a defined threshold, models can now estimate how long until symptoms emerge, with a typical margin of error of about three to four years. Older adults progress faster once they cross that threshold.
This means the test isn't just a yes/no diagnostic, it has become an Alzheimer's "clock."
From Research Lab to Doctor's Office
FDA Clearance: A Milestone Moment
In May 2025, the U.S. Food and Drug Administration cleared the Lumipulse G pTau217/β-amyloid 1-42 Plasma Ratio, making it the first blood test cleared to aid in diagnosing Alzheimer's disease by detecting amyloid-associated pathology. It is indicated for symptomatic adults aged 55 and older.
The FDA's decision noted that this blood-based ratio correlates with amyloid PET scans and CSF markers, and can reduce the need for expensive or invasive confirmatory testing. It is approved as an aid to diagnosis, not as a stand-alone definitive test.
Now Available at Major Reference Labs
Several commercially available p-tau217 tests are now offered through major clinical labs. These include:
• Quest Diagnostics AD-Detect p-tau217 — available by physician order
• PrecivityAD2 — a percentage-based p-tau217 test used in both clinical and research settings
• LucentAD p-tau217 — available through specialty labs
• ARUP Laboratories and Mayo Clinic — both now offer plasma p-tau217 testing as part of cognitive evaluation panels
These tests are generally ordered by a physician, such as a neurologist, geriatrician, or primary care provider, and are designed for adults over 50–60 who are being evaluated for memory concerns or suspected cognitive decline.
How to Get Tested
If you or a loved one is experiencing memory concerns or early cognitive symptoms, here is how to access p-tau217 testing today:
1. Talk to your doctor. A doctor can order a p-tau217 blood test as part of a cognitive evaluation. Ask specifically about "plasma p-tau217" or "AD blood biomarker testing."
2. Request a referral to a memory clinic. Academic medical centers and memory disorder clinics often have the most current testing panels available, including research-grade assays.
3. Ask about clinical trial eligibility. If you have a family history of Alzheimer's or carry the APOE4 gene, you may qualify for prevention trials that provide free biomarker testing. Clinicaltrials.gov is a good place to search.
4. Understand the context. A positive p-tau217 result should be interpreted alongside your clinical history and, when needed, confirmed with imaging or CSF testing, especially before starting any therapy. Professional guidelines emphasize that blood biomarkers are aids to diagnosis, not the final word.
Important: Current professional guidance from the Alzheimer's Association states that p-tau217 testing is intended for adults with cognitive symptoms or high-risk profiles, not as a general screening test for asymptomatic people. This may change as the field evolves.
What This Means for Prevention
In 2020, we speculated that if people could know they were progressing toward Alzheimer's two decades before symptoms, they might implement diet and lifestyle changes that could alter the course of the disease. That idea is now being actively tested.
The ability to identify people in the pre-symptomatic phase — and estimate how far they are from symptom onset — creates a window for intervention that simply didn't exist before.
Researchers are now enrolling people with elevated p-tau217 into trials testing anti-amyloid and anti-tau therapies, as well as lifestyle interventions involving exercise, diet, sleep, and cardiovascular risk reduction.
The bottom line: in 2020, we told you a revolution was coming. As of 2026, it has arrived. The test that was once a research finding is now a clinical tool and for people with symptoms or a family history of Alzheimer's disease, it is worth asking your doctor about today.
Summary
A blood biomarker known as p-tau217 can detect Alzheimer’s-related brain changes years before symptoms develop. Since early research in 2020, the science has strengthened dramatically. In 2025, the FDA cleared the first blood test using this biomarker to aid diagnosis, and major labs now offer it. Studies show the test can identify Alzheimer’s pathology with accuracy approaching PET scans and spinal fluid tests. Researchers have also discovered that p-tau217 levels can help estimate how long it may take for symptoms to appear. This advancement may allow earlier diagnosis, improved clinical trial recruitment, and new opportunities for prevention strategies.
Frequently Asked Questions
What is the p-tau217 blood test?
It is a blood test that measures a protein linked to Alzheimer’s disease pathology. Elevated levels suggest the presence of Alzheimer’s-related brain changes.
How early can the test detect Alzheimer’s disease?
Research suggests p-tau217 levels may begin rising up to 20 years before symptoms such as memory loss appear.
Is the test approved by the FDA?
Yes. In 2025, the FDA cleared the Lumipulse G pTau217/β-amyloid plasma ratio test to aid in diagnosing Alzheimer’s disease.
Who should consider getting tested?
Doctors currently recommend the test primarily for adults over 55 experiencing cognitive symptoms or those being evaluated for possible Alzheimer’s disease.
Can the test predict when symptoms will start?
Emerging research suggests p-tau217 levels may help estimate how far someone is from developing symptoms, though it is not yet precise enough to predict exact timing.
The Expert:
